Drug Approval | May 29, 2025
Zydus receives USFDA ‘Fast Track Designation’ for novel oral inhibitor ‘Usnoflast’
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
Ideal for extreme dry skin and hyperkeratotic conditions such as psoriasis and ichthyosis, Ureaderm offers the next step in evidence-based, effective skin hydration
A new weapon in the global fight against malaria
Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74
The Atlan A100 system delivers advanced ventilation technology for adults, pediatric patients, and neonates, revolutionizing care with seamless workflows across hospital departments
Data highlight ambition to transform prevention and treatment for serious bacterial infections and develop novel preventative strategies for respiratory viral infections
The first-of-its-kind study will evaluate potential association between GSK’s shingles vaccine and reduced dementia risk, building on growing body of evidence from observational and retrospective studies
Adults taking Mounjaro with diet and exercise in a controlled clinical trial lost on average 21.8 kg at the highest dose (15mg) and 15.4 kg at the lowest dose (5mg)
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
TB treatment coverage in India increased by 32% in the last eight years from 53% in 2015 to 85% in 2023
Subscribe To Our Newsletter & Stay Updated
